Biotech News
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
ir.foghorntx.com2026-05-07 11:08 EST
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND